Disease-duration based comparison of subsets of immune cells in SARS CoV-2 infected patients presenting with mild or severe symptoms identifies prognostic markers for severity

Archana Kulkarni-Munje1 | Sonali Palkar2 | Shubham Shrivastava1 | Sanjay Lalwani2 | Akhilesh C. Mishra1 | Vidya A. Arankalle1

1Department of Communicable Diseases, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to be University), Pune, India
2Department of Paediatrics, Bharati Vidyapeeth Medical College, Bharati Vidyapeeth (Deemed to be University), Pune, India

Correspondence
Dr. Vidya A. Arankalle, Department of Communicable Diseases, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to be University), Pune, India.
Email: varankalle@yahoo.com

Funding information
Biotechnology Industry Research Assistance Council (BIRAC), Grant/Award Number: BIRAC/BT/NBM0095/02/18

Abstract

Introduction: Infection with SARS-CoV-2 leads to a spectrum of symptoms. Understanding the basis for severity remains crucial for better management and therapy development. So far, older age, associated comorbidities, and IL-6 have been associated with severity/mortality.

Materials and Methodology: As a primary step, we analyzed the frequency and functional profile of innate immune cells (NK cells/dendritic cells/monocytes) and adaptive immunity-driving lymphocytes (B cells/T cells/follicular T helper cells) by flow cytometry. Sixty cases of SARS CoV-2 infection (25 severe, 35 mild) and ten healthy subjects without SARS CoV-2 IgG were included. Disease-duration based analysis of immune profile was explored for early events differentiating the two disease forms. Neutralizing antibody titers were determined by PRNT.

Results and Conclusion: Disease severity was found to be associated with impaired maturation of mDCs and hyperactivation of NK, follicular T helper cells, and CD8 T cells. Lower IL-21 receptor expression on memory B cells indicated an imbalance in IL-21/IL-21 R ratio. Lower BCMA positive plasmablast cells in severe cases did suggest a probable absence of long-term humoral immunity. Multivariate analysis revealed a progressive association of PD-1+CD4 T cells with PRNT50 titers. Thus, in addition to identifying probable prognostic markers for severity, our study emphasizes the definite need

List of abbreviations: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; PRNT50, plaque reduction neutralization test at 50% reduction; IL-6, interleukin-6; IL-4, interleukin-4; IL-10, interleukin-10; IL-2, interleukin-2; NK cells, natural killer cells; IL-21, interleukin-21; BCMA, B cell maturation antigen (CD269); PBMC, peripheral blood mononuclear cells; COVID-19, coronavirus disease 2019; T_{FH}, follicular T helper cells; ICOS, inducible T-cell costimulator; PD-1, programmed death -1; CXCR5, C-X-C chemokine receptor type 5; pDC, plasmacytoid dendritic cells; mDC, myeloid dendritic Cells; TCR, T cell receptor; BAFF, B-cell activating factor; IFN-γ, interferon gamma; TNF-α, tumor necrosis factor alpha; MEM, minimum essential medium; pfu, plaque forming units; ACE2, angiotensin-converting enzyme 2; MFI, mean fluorescent Intensity; Mcl-1, myeloid cell leukemia-1; IQR, interquartile range; CXCR5, C-X-C chemokine receptor type 5 (CD185); IL-21R, IL-21 receptor (CD360).

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 John Wiley & Sons Ltd.
1 | INTRODUCTION

The ongoing pandemic of SARS-CoV-2 has turned out to be an unprecedented threat to global public health and the economy. Irrespective of the degree of industrialization or availability of medical infrastructure, all populations have been (and are being) affected. The number of cases worldwide and corresponding mortality rates are 31.6 million and 3.7% respectively.1

The disease, COVID-19, varies from an asymptomatic infection and self-limiting mild disease to severe acute respiratory distress, multiorgan failure followed by recovery or fatal outcome. For any pathogen leading to variable clinical presentations and mortality, understanding of pathogenesis is of utmost importance. Initial studies identified older age and pre-existing chronic conditions such as diabetes, hypertension, cardiovascular diseases, cancer, etc., as high-risk factors for disease severity.2 Viral sequence variation was not related to severity3 and similar viral loads were detected in symptomatic and asymptomatic patients.3

The major focus of the scientific community has been to unravel the immunopathogenesis of the disease requiring a clear understanding of the immune response in both mild and severe disease forms. Due to the high transmissibility of the virus and biosafety concerns, studies are predominantly limited to blood investigations. An association of cytokine storm including high levels of interleukin IL-6 production with severe disease signifies pathological immune dysregulation.4,5,6 Recent data suggest that antibody response is higher in severe disease.7 Though studies on innate immunity are limited,8 T cell and B cell responses are being actively investigated9-11

In India, the first COVID case was reported on 30th January 2020. As of today, (September 23, 2020) 5.73 million confirmed cases with >91,000 deaths have been reported. Older age and existing comorbidities remain the high-risk factors. Of note, we observed significantly higher OD values in the ELISA12 and neutralizing antibody titers in PRNT (unpublished observations) in patients with severe disease than those presenting with mild infection. In view of the need to understand immunology of the disease in general and among the Indian population in particular, we attempted to explore the functional profile of innate immune cells (monocytes, dendritic cells, and NK cells), and adaptive immune cells (B cells, follicular T helper cells, CD4 T, and CD8 T cells) in SARS CoV-2 infected individuals presenting with asymptomatic, mild, or severe disease. Further, the dynamics of these immune cells and, relation to neutralizing antibody titers was analyzed. We found that certain earlier modulations observed during the first week of disease could differentiate between mild and severe infections.

2 | METHODS

2.1 | Study design and participants

This study was approved by the human ethics committee of Bharati Vidyapeeth (Deemed to be University) hospital and Medical college. A subset of patients attending Bharati Hospital, Pune, India, with confirmed positive test for SARS-CoV-2 reverse-transcriptase-polymerase chain reaction (RT-PCR), from 20th April 2020 to 11th June 2020, was enrolled. The patients were divided into severe and mild groups according to their clinical presentation.13 All the patients were admitted to a special COVID facility at Bharati Hospital and research center, Pune, a tertiary care hospital.

After informed consent, approximately 5 ml of blood from all these patients and controls were collected in EDTA and processed for PBMC and plasma separation by ficoll-histopaque based density gradient method. Plasma was used for Th1 and Th2 cytokine profiling (IFN-γ, TNF-α, IL-4, IL-10, IL-6, and IL-2) by cytometric bead array kit (BD Biosciences) and detection/quantitation of neutralizing antibodies (Nabs) using 50% plaque reduction neutralization test (PRNT50). PBMCs were subjected for immunophenotyping for selected immune cells and their subpopulations using appropriate fluorochrome-labeled antibodies (Biolegend, San Diego & BD Biosciences) by polychromatic flow cytometry approach using CytoFLEX LX platform (Beckman Coulter). Briefly, after trypan blue-based live cell count, PBMCs were subjected for surface staining procedure using fluorochrome-labeled antibody cocktails (list of antibodies is provided in supplementary Information) followed by fixation (PBS with 3% paraformaldehyde). The intracellular proteins were detected after permeabilizing (BD FACs perm-II) the fixed PBMCs for in-depth viral antigen-specific functional analyses in a larger patient cohort and with multiple sampling.

KEYWORDS

adaptive immune cells, disease severity, innate immune cells, PRNT50, SARS CoV-2
with the help of appropriate fluorochrome-labeled antibodies (Supporting Information Table). Using forward and side scatter, the lymphocyte and lympho-monocyte populations were gated while acquiring the samples, and 50,000 gated events were recorded. The cells and the subpopulations studied are enlisted in Table 1. The gating strategy is depicted in Figure 1.

### 2.2 Determination of SARS CoV-2 PRNT<sub>50</sub>

For PRNT<sub>50</sub>, one day before infection, 1 × 10<sup>5</sup> Vero cells/ml were seeded in 24-well plate using MEM containing 10% FBS and antibiotics. 1:5 diluted serum samples were heat-inactivated for 30 min at 56°C. Four-fold serial dilution was performed and mixed with an equal volume of 20–40 pfu of SARS CoV-2. The serum-virus mixture was incubated for 1 h at 37°C in a humidified incubator with 5% CO<sub>2</sub>. After incubation, 100 µL of the mixture was added in duplicate to 24-well plate and incubated for 1 h at 37°C in humidified incubator with 5% CO<sub>2</sub>. After incubation, 1 ml of 1% overlay media containing MEM, Aquacide-II (Merck), 2% FBS and antibiotics was added to the Vero cell monolayer. Plates were incubated for 5 days at 37°C in a humidified incubator with 5% CO<sub>2</sub>. Five days postinfection, overlay media was discarded, cells were fixed using 3.7% formaldehyde and after washing with PBS, cells were stained using 1% crystal violet. Plates were washed and kept for air dry. Plaques were counted manually and PRNT<sub>50</sub> titer was determined using Karber’s formula as described earlier. Samples with PRNT<sub>50</sub> titer ≥20 were considered seropositive.

### 2.3 Statistical analysis

Statistical analysis was performed using SPSS 20.0 software and Graph Pad Prism 5.0 software. Median and interquartile range (IQR) were used to describe continuous variables. Mann-Whitney U test was used to compare the median for continuous variables between the study groups. For univariate and multivariate analysis, R programming was used.

### 3 RESULTS

#### 3.1 Study population

The study included 60 COVID-19 patients and 10 apparently healthy individuals negative for IgG-anti-SARS-CoV2 antibodies. Patients admitted to intensive care units for oxygen/ventilator support were designated as suffering from a severe disease (SD, n = 25) while those with mild (n = 20) or no (n = 15, asymptomatic) symptoms were classified as MD. Among the SD patients, four succumbed to infection while 21 were discharged. Follow up blood samples collected from SD (n = 15) and MD (n = 5) patients were also studied. The demographic characteristics of the study participants are shown in Table 2. COVID-19 cases showed a marked lymphopenia

### Table 1 Immune cell subsets analyzed in COVID-19 cases and control subjects

| No | Major cell types | Cell subsets | Subpopulation |
|----|-----------------|-------------|--------------|
| 1  | T cells (CD3+ cells) | CD4 T cells (CD3+ CD4+) | IL-2+CD4, and CD40L+CD4 T cells |
|    |                  | T<sub>FH</sub> (CD3+CD4+CXCR5+PD-1) | ICOS+IL-21+T<sub>FH</sub> cells |
|    |                  | CD8 T cells (CD3+CD8+) | CD38+HLA DR + CD8 T cells |
| 2  | B cells (CD3+CD19+) | Memory B cells (CD3-CD19+ CD27+) | Switched memory B cells (CD3-CD19+ CD27+IgD-) |
|    |                  | Plasmablast cells (CD3-CD19+CD138+) | Unswitched memory B cells (CD3-CD19+ CD27+IgD+) |
| 3  | NK cells | Total NK cells (CD3-CD16+CD56+)+(CD3-CD16-CD56+) | Only CD107a +Total NK cells |
| 4  | Dendritic cells | Myeloid dendritic cells (mDC) (Lineage - HLADR + CD11c +CD1c+) | CD80+CD86+ mDC |
|    |                  | Plasmacytoid Dendritic cells (pDC) (Lineage - HLADR + CD11c -CD123+) | CD80+CD86+ pDC |
| 5  | Monocytes | CD3-CD14+ | CD3-CD14+CD16- and CD3-CD14+CD16+ |
as evidenced by lower lymphocyte percentage (median 28.83%) as compared to the control subjects (median 61.06%) \((p < .0001)\).

To understand the contribution of major immune cell subsets in the pathogenesis of SARS CoV-2 infection, we evaluated the frequencies of antigen-presenting cells (dendritic cells and monocytes), natural killer cells, T cells (CD4 T cells, CD8 T cells, and follicular T helper cells \(T_{FH}\)) and B cell subsets (memory B cells and plasmablast cells). Cytokine storm involving a major role of IL-6 was already documented and hence we analyzed Th1 (IFN-\(\gamma\), TNF-\(\alpha\), and IL-2) and Th2 (IL-4, IL-6, and IL-10) plasma cytokine levels to delineate association with these cells if any. Table 3 provides the median and IQR of different immune cell subsets with associated markers in different study groups.

### 3.2 Mild symptomatic versus asymptomatic COVID-19

Initially, we compared mild symptomatic and asymptomatic individuals with respect to all the parameters.
### Comparison of Immune profiles in patients with mild or severe clinical presentation

| Immune parameters | Mild (N = 35) Median (IQR) | Severe (N = 25) Median (IQR) | p value | Mild versus Severe (Mann–Whitney U test) Median (IQR) | Controls (N = 10) | p value | Mild versus Controls (Mann–Whitney U Test) |
|-------------------|-----------------------------|-------------------------------|---------|-----------------------------------------------------|-------------------|---------|-----------------------------------------|
| Myeloid DC % Total | 0.43 (0.19–0.86)            | 0.21 (0.02–0.65)              | 0.056   | 0.61 (0.37–0.73)                                    | 0.56              |         |                                         |
| mDC (CD80+ & CD86+) % | 87.42 (84.2–90.68)         | 56.89 (41.57–77.59)           | p<0.0001 | 88.52 (86.4–92.13)                                  | 0.28              |         |                                         |
| CD80 MFI mDC (CD80+ & CD86) | 8976 (7747–10795) | 8364 (6591–11,277) | 0.333 | 9403 (8235–10583)                                  | 0.67              |         |                                         |
| CD86 MFI (CD80+ and CD86+) | 6265 (5127–8107) | 2708 (2144–4829) | 0.001 | 8628 (7695–9996)                                  | 0.01              |         |                                         |
| Plasmacytoid DC % Total | 0.17 (0.10–0.26)            | 0.07 (0.02–0.21)              | 0.005   | 0.37 (0.28–0.54)                                    | 0.01              |         |                                         |
| CD80+ pDC % | 57.27 (40.08–67.1)         | 42.55 (19.05–73.68)           | 0.164   | 67.96 (51.94–85.98)                                  | 0.05              |         |                                         |
| CD80 MFI (pDC) | 6025 (5293–8874)           | 7897 (6318–12284)             | 0.047   | 6555 (6222–7968)                                    | 0.17              |         |                                         |
| CD86+ pDC % | 24.75 (13.77–37.49)        | 20.83 (0–43.81)               | 0.692   | 18.4 (9.59–41.11)                                   | 0.86              |         |                                         |
| CD 86MFI (pDC) | 390.6 (352–578.3)           | 622 (445.7–775.1)             | 0.863   | 524 (319–564.6)                                     | 0.6               |         |                                         |
| Monocyte % Total | 1.925 (0.57–2.98)           | 1.74 (0.65–3.56)              | 0.872   | 1.71 (0.8–3.56)                                     | 0.97              |         |                                         |
| CD16+ monocyte % | 11.96 (6.91–16.66)         | 17.87 (5.53–25.73)            | 0.301   | 4.91 (4.45–8.44)                                    | 0.02              |         |                                         |
| Total NK% | 8.52 (4.76–12.4)           | 7.74 (5.105–18.24)            | 0.567   | 7.08 (3.42–10.68)                                   | 0.76              |         |                                         |
| IFN-γ & CD107a+ total NK% | 0.06 (0–0.32)               | 1.17 (0.09–4.88)              | 0.001   | 1.11 (0–3.43)                                       | 0.05              |         |                                         |
| Only CD107a+ total NK% | 11.69 (6.79–24.39)         | 18.03 (9.71–31.25)            | 0.305   | 19.71 (8.46–27.7)                                   | 0.34              |         |                                         |
| Only IFN-γ + total NK% | 0 (0–0.038)                | 0 (0–2.4)                     | 0.007   | 0 (0–0.63)                                          | 0.2               |         |                                         |
| CD8% | 32.04 (22.3–41.45)         | 30.64 (25.63–40.54)           | 0.792   | 34.62 (26.63–40.29)                                  | 0.42              |         |                                         |
| HLA DR and CD38 + CD8% | 0.13 (0.02–0.78)            | 2.12 (0.61–8.36)              | 0.0001  | 0.08 (0.01–0.11)                                    | 0.2               |         |                                         |
| CD4% | 60.93 (49.53–68.25)        | 54.9 (41.32–66.2)             | 0.215   | 53.44 (47.89–61.45)                                  | 0.18              |         |                                         |
| CD40L+ CD4% | 6.09 (3.305–11.97)          | 8.04 (6–13.82)                | 0.356   | 4.58 (3.35–7.93)                                    | 0.43              |         |                                         |
| CD40L MFI | 21399 (20164–23105)       | 24397 (22559–25459)           | <0.0001 | 19,521 (19,134–20,993)                               | 0.01              |         |                                         |
| IL-2 + CD4% | 0.02 (0.01–0.06)            | 0.205 (0.08–1.68)             | <0.0001 | 0.01 (0–0.07)                                       | 0.01              |         |                                         |
| IL-2 MFI | 2425 (1983–4385)           | 1769 (1637–2076)              | 0.071   | 2247 (2171–4494)                                    | 0.61              |         |                                         |
| CD4/CD8 | 1.81 (1.165–3)            | 1.7 (1.1–2.54)                | 0.587   | 1.43 (1.12–1.77)                                    | 0.21              |         |                                         |
| TFH % | 0.09 (0.02–0.22)           | 1 (0.525–1.845)               | <0.0001 | 0.1 (0.03–0.24)                                     | 0.79              |         |                                         |
| CXCR5+CD4% | 14.62 (9.59–20.03)         | 23.43 (12.46–41.77)           | 0.031   | 13.58 (10.38–16.52)                                  | 0.96              |         |                                         |
| PD-1+ CD4% | 0.34 (0.155–1.39)           | 1.84 (0.67–3.01)              | 0.009   | 0.29 (0.2–0.54)                                     | 0.88              |         |                                         |
| ICOS and IL-21 + cells % | 75 (50–100)                | 71.09 (59.33–79.87)           | 0.546   | 56.42 (86.37)                                       | 0.71              |         |                                         |
| IL-21 MFI | 14979 (13186–21545)        | 18814 (15943–22635)           | 0.015   | 15223 (1359–19936)                                   | 0.28              |         |                                         |
| ICOS MFI | 9384 (7512–13657)          | 10708 (9177–14010)            | 0.12    | 9603 (7954–11591)                                    | 0.42              |         |                                         |
| Immune parameters | Mild (N = 35) Median (IQR) | Severe (N = 25) Median (IQR) | Mild versus severe (Mann–Whitney U test) p value | Controls (N = 10) Median (IQR) | Mild versus Controls (Mann–Whitney U Test) p value |
|-------------------|-----------------------------|-------------------------------|---------------------------------------------|--------------------------------|---------------------------------------------|
| **B cells**       |                             |                               |                                             |                                |
| B cells %         | 10.89 (8.53–16.47)          | 6.02 (2.15–17.1)              | 0.134                                       | 13.6 (5.2–16.3)                | 0.22                                        |
| Memory B cells %  | 23.22 (14.42–31.8)          | 36.04 (21.73–43.01)          | 0.01                                        | 26.9 (15.23–39.68)             | 0.52                                        |
| Class switched memory B cells % | 90.65 (81.08–93.67) | 90 (84.14–94.52) | 0.741                                       | 89.35 (80.02–96.37)            | 0.83                                        |
| Unswitched memory B cells % | 7.82 (5.7–17.08)       | 10 (4.79–15.2)               | 0.952                                       | 12.63 (5.23–16.78)             | 0.7                                         |
| IL-21 R + memory B cell % | 6.36 (1–35.69)             | 7.85 (2.36–29.65)            | 0.533                                       | 8.65 (3.68–23.56)              | 0.21                                        |
| IL-21 R MFI       | 865.4 (325.2–2541)         | 1324 (457.2–3548)            | 0.645                                       | 2123 (1632–2152)               | <0.0001                                     |
| **Plasmablast cells** |                           |                               |                                             |                                |
| Plasmablast cells % | 9.9 (3.8–12.25)            | 10.72 (3.78–14.57)           | 0.852                                       | 3.21 (1.01–6.23)               | <0.0001                                     |
| BCMA + plasmablast cells % | 26.09 (15.85–30.43)       | 14.7 (8.95–27.53)            | 0.072                                       | 25.87 (21.06–28.3)             | 0.76                                        |
| BCMA MFI          | 29989 (14346–34433)        | 30,816 (18,297–41,842)       | 0.724                                       | 28,965 (26,771–43,781)         | 0.67                                        |
| **Plasma Th1 cytokine level (pg/ml)** |                     |                               |                                             |                                |
| IFN-γ             | 0.32 (0–1.54)              | 0.43 (0.12–0.83)             | 0.953                                       | 0.29 (0–1.17)                  | 0.15                                        |
|                  | 0 (0–0.24)                | 0 (0–0.24)                   | 0.733                                       | 0.24 (0–0.85)                  | 0.8                                         |
|                  | 0.155 (0–0.5)             | 0.22 (0–0.39)                | 0.952                                       | 0 (0–0.25)                     | 0.06                                        |
| **Plasma Th2 cytokine level (pg/ml)** |                     |                               |                                             |                                |
| IL-10             | 0.465 (0.08–1.37)          | 2.53 (0.67–16.9)             | 0.0004                                      | 0.39 (0.24–0.65)               | 0.12                                        |
| IL-6              | 4.22 (2.05–6.80)           | 33.78 (4.36–257.5)           | 0.001                                       | 1.03 (0–2.65)                  | <0.0001                                     |
| IL-4              | 0.68 (0.31–1.32)           | 0.43 (0–0.89)                | 0.121                                       | 0 (0–1)                       | 0.01                                        |
examined. Except for TNF-α levels, the other parameters were comparable among these patient groups. TNF-α was detected in the asymptomatic patients (median 0.125 pg/ml [0–0.45]) while this cytokine was undetectable in the symptomatic cases (p = .027). Therefore, the two groups were combined (MD) while comparing with the patients with severe disease (SD).

### 3.3 Compromised antigen presentation in COVID-19 and hyperactivation of NK cells

DC population was significantly affected by the virus infection. The proportion of total mDCs was not different among the two groups at p = .056 level. SD patients exhibited a lower frequency of mDCs with the mature phenotype (CD80 and CD86 mDCs) than recorded in the MD group (p < .0001). CD86 expression density was significantly lower in MD patients reducing further in the SD category (p < .001 for both). Plasmacytoid DCs were lower in both MD and SD patients, severe category exhibiting further reduction (p < .005). In the SD patients, pDCs showed lower expression of the maturation marker, CD80 (p = .047). Thus, the disease induced a strident defect in the maturation of the dendritic cell population that was aggravated in severe disease (Table 3; Figure 2A).

Although monocyte frequencies were intact, a large subset of monocytes was found to be CD16+, that is, nonclassical monocytes (Table 3; Figure 2B). While the total NK cell pool was unaffected, degranulation phenotype along with IFN-γ was augmented in the SD patients as compared to MD cases (p = .001; Table 3; Figure 2C,D)

### 3.4 Hyperactivation of T<sub>FH</sub> and CD8 T cells

In contrast to the recent findings of significant depletion of T cells in SARS Cov-2 infection, T cell frequencies and CD4/CD8 ratio remained unchanged among both the patient groups (Table 3; Figure 3A,B). Although the CD8 T cell compartment was unchanged with respect to quantity, activation of these cells was evident by higher expression of HLA DR and CD38 expression in the SD patients than the MD group (p = .0001) (Table 3; Figure 3C).

In MD patients, CD4 T cells exhibited higher expression of CD40L (p = .009) that was further enhanced in the SD category (p < .0001). The proportion of IL-2+
CD4 T cells was higher in the SD patients while the levels among MD patients and controls were comparable (Figure 3D). In SD patients, the proportion of T_{FH} (CXCR5 + PD-1+ CD4+ T cells ($p = .0001$), CXCR5+CD4+PD-1- T cells ($p = .03$), and PD-1+CD4 T cells ($p = .009$) was higher than in the MD group. However, IL-21 and ICOS expression by these subsets remained comparable between SD & MD patients (Table 3; Figure 3E,F).

### 3.5 Quantitative and qualitative loss of B cell compartment

Although the total B cell frequency remained unchanged, the SD patients exhibited a higher frequency of memory B cells than the MD group (Table 3; Figure 4A,B). The class switched and unswitched memory B cells percentages were comparable among all the groups (Table 3; Figure 4C). Even though the frequency of IL-21R positive memory B cells was unchanged, the IL-21 receptor expression intensity (MFI) was lower in MD patients when compared to the controls ($p < .0001$). No difference was recorded among MD and SD groups. In addition, a sharp rise in plasmablast cells was evident in the MD patients ($p < .0001$) that remained comparable in the SD group. (Table 3; Figure 4D)

### 3.6 Plasma cytokine profile: An indication of immune paralysis

In line with previous findings, plasma cytokine profiling revealed the dominance of IL-6 secretion in COVID-19 patients ($p = .001$) which was more pronounced in severe cases than in mild disease ($p = .001$). IL-10 levels were also higher in severe disease ($p = .0004$). Only mild disease showed a significant rise in IL-4 ($p = .01$) as compared to the controls (Table 3; Figure 5A,B).

In view of the observed decline in the frequency of myeloid dendritic cells, we compared cytokine profiles of MD and SD patients with or without mDC reduction. Analyses revealed that in the mild patients, plasma IL-4 levels increased with rise in mDC frequency ($p = .023$). No such difference was recorded in the SD patients.

### 3.6.1 Neutralizing antibody titers in relation to the parameters investigated

In accordance with our earlier observations, severe disease was characterized by higher neutralizing antibody titers. During the first 2 weeks, PRNT_{50} titers were significantly higher in the SD patients (median: 571.1) than the MD group (median: 53.05, $p = .010$; Figure 4E). Therefore, the proportions and effector functions of
FIGURE 4  Adaptive immune response in relation to COVID-19 disease severity (B cells and plasmablasts): Vertical scatter plots denote the comparisons of frequencies of B cells and plasmablast populations and their subpopulations among different study groups: (A) B cells, (B) Memory B cells, (C) Class switched and unswitched memory B cells, (D) Plasmablasts cells & BCMA+plasmablast cells, (E) SARS CoV-2 PRNT50 titers in mild (median: 53.05; IQR: 22.49–294.8) and severe cases (median: 571.1; IQR: 50.31–2247) within 15 days of disease onset. (F) Association of SARS CoV-2 PRNT50 titers (15 days of disease onset) with PD-1+CD4 T cells. (G) Association of SARS CoV-2 PRNT50 titers (15 days of disease onset) with memory B cells. (Mann–Whitney U test; Error bars, median and IQR). IQR, interquartile range.
immune cells and cytokines were compared in relation to neutralizing antibody titers in these groups. In univariate analysis, CD86+ pDC ($p = .017$), PD-1+CD4 ($p = .0051$; Figure 4F) and memory B cells ($p = .00982$; Figure 4G) correlated with PRNT50 titer. However, in multivariate analysis, PD-1+CD4 emerged as the single variable influencing PRNT50 titers ($p = .003$, $R^2 = 0.421$). As mentioned earlier, PD-1 expression on CD4 T cells was higher in severe disease.

3.6.2 | Relationship of disease duration and modulation of parameters examined in the SD and MD patients

Next, we compared the proportion of immune cells and cytokine concentrations in the MD and SD patients at different time points after the onset of clinical symptoms (Table 4). These comparisons revealed the following patterns in the SD patients: (1) Lowering of activated mDCs (CD80+ and CD86+) and increase in TFH cells that continued till the 3rd-week postonset; (2) lower pDCs and a marginal reduction in B cells during the 2nd week ($p = .061$) and higher IL-2+CD4 cells during the first two weeks; (3) difference only in the first week; increase in HLA DR & CD38+ CD8 and memory B cells and decrease in BCMA + plasmablast cells; (4) modulation during 2nd week, decrease in CD16+ Monocytes and reduction in total NK cells.

3.7 | Immune cells/cytokines at the time of first and last sampling in the COVID19 patients

Follow up samples were available from 15 SD and 5 MD patients. A significant decline in IL-21R positive memory B cells ($p = .021$) and NK cell function in terms of degranulation ($p = .015$) and IFN-γ secretion ($p = .019$) capacity of NK cells was noted in the SD patients (Figure 6A,B,C). In the MD patients, except for the rise in CD86 MFI on myeloid DCs ($p = .043$), other immune cells and cytokines remained unchanged (Figure 6D).

4 | DISCUSSION

This study reports alterations in the circulating immune cells and cytokines associated with innate and adaptive immune responses in COVID-19. We first compared all the MD and SD patients irrespective of the duration of disease onset (Table 3). However, when the same parameters were compared with respect to disease duration and severity, differential modulations were obvious and are discussed here.

4.1 | Innate immune response

So far, understanding of innate immune response to SARS CoV-2 is limited. We assessed the proportions and effector functions of three important cell populations of the innate immune system, that is, dendritic cells, monocytes, and NK cells. Interestingly, a reduction in dendritic cells was found in the SD patients (Table 4). Comparison in relation to disease duration revealed an association of early (first week) reduction of mDCs with the mature phenotype (CD80 and CD86) and total pDCs with severe disease that continued for at least 2 weeks (Table 4). Interestingly, patients with lower frequency of mDCs exhibited lower plasma IL-4 levels. Role of IL-4 in the process of maturation of dendritic cells is well documented. For the first time, we show that early
| Name of Immune cell subset | Type of illness | Week 1 Mann–Whitney U | Week 2 Mann–Whitney U | Week 3 Mann–Whitney U | Week 4 Mann–Whitney U |
|---------------------------|-----------------|------------------------|------------------------|------------------------|------------------------|
| mDC (CD80+ and CD86+) %   | Mild            | 87.6                   | 0.007                  | 87.8                   | 0.001                  | 87.7                   | 0.013                  | 87.8                   | 1                      |
|                           | Severe          | 31.77                  |                        | 33.33                  |                        | 56.02                  |                        | 83.35                  |                        |
| Plasmacytoid DC %         | Mild            | 0.17                   | 0.012                  | 0.11                   | 0.032                  | 0.15                   | 0.276                  | 0.13                   | 0.121                  |
|                           | Severe          | 0.06                   |                        | 0.03                   |                        | 0.01                   |                        | 0.06                   |                        |
| CD4%                      | Mild            | 56.8                   | 0.19                   | 59.3                   | 0.753                  | 57.08                  | 0.355                  | 58.12                  | 0.121                  |
|                           | Severe          | 71.08                  |                        | 63.7                   |                        | 60.64                  |                        | 10.735                 |                        |
| TFH %                     | Mild            | 0.15                   | 0.001                  | 0.15                   | 0.012                  | 0.17                   | 0.045                  | 0.16                   | 0.121                  |
|                           | Severe          | 1.29                   |                        | 1.07                   |                        | 1.04                   |                        | 5.77                   |                        |
| IL-21 MFI (T F H )        | Mild            | 18836                  | 0.28                   | 14852                  | 0.038                  | 16471                  | 0.165                  | 15160                  | 0.121                  |
|                           | Severe          | 21875                  |                        | 21751                  |                        | 17500                  |                        | 15178                  |                        |
| CD16+ monocytes %         | Mild            | 30.37                  | 0.165                  | 10.16                  | 0.025                  | 10.16                  | 1                      | 10.16                  | 1                      |
|                           | Severe          | 13.22                  |                        | 17.86                  |                        | 12.39                  |                        | 18.3                   |                        |
| Total NK %                | Mild            | 7.6                    | 0.316                  | 6.2                    | 0.042                  | 6.38                   | 0.355                  | 6.29                   | 1                      |
|                           | Severe          | 2.88                   |                        | 2.65                   |                        | 3.03                   |                        | 8.866                  |                        |
| HLA DR + CD38 + CD8%      | Mild            | 0.495                  | 0.041                  | 0.16                   | 0.414                  | 0.29                   | 0.122                  | 0.18                   | 1                      |
|                           | Severe          | 3.69                   |                        | 2                      |                        | 3.03                   |                        | 4.05                   |                        |
| IL-2 + CD4%               | Mild            | 0.13                   | 0.005                  | 0.03                   | 0.016                  | 0.06                   | 0.06                   | 0.035                  | 1                      |
|                           | Severe          | 0.49                   |                        | 0.47                   |                        | 0.3                    |                        | 0.015                  |                        |
| B Cells %                 | Mild            | 13.44                  | 0.033                  | 10                     | 0.061                  | 13.01                  | 0.64                   | 11.5                   | 0.439                  |
|                           | Severe          | 4.63                   |                        | 6.93                   |                        | 7.47                   |                        | 13.66                  |                        |
| Memory B cells %          | Mild            | 14.3                   | 0.001                  | 25.76                  | 0.116                  | 31.26                  | 0.355                  | 28.73                  | 0.121                  |
|                           | Severe          | 41                     |                        | 42.86                  |                        | 34.78                  |                        | 42.84                  |                        |
| Class Switched memory B cells % | Mild | 81.15                  | 0.589                  | 89.31                  | 0.586                  | 88.22                  | 0.537                  | 88.76                  | 0.439                  |
|                           | Severe          | 85.23                  |                        | 86.53                  |                        | 90.02                  |                        | 81.73                  |                        |
| Unswitched memory B cell% | Mild            | 18.27                  | 0.643                  | 10.27                  | 0.66                   | 10.97                  | 0.436                  | 10.28                  | 0.425                  |
|                           | Severe          | 14.03                  |                        | 12.61                  |                        | 10                     |                        | 16.58                  |                        |
| BCMA+plasmablast cell %   | Mild            | 23.7                   | 0.02                   | 21.32                  | 0.136                  | 23.56                  | 0.563                  | 25.32                  | 0.935                  |
|                           | Severe          | 13.23                  |                        | 10.25                  |                        | 12.34                  |                        | 21.25                  |                        |
| BCMA MFI                  | Mild            | 25326                  | 0.82                   | 34215                  | 0.996                  | 27896                  | 0.036                  | 36547                  | 0.865                  |
|                           | Severe          | 21457                  |                        | 26359                  |                        | 21789                  |                        | 39875                  |                        |
| IL-6 pg/ml                | Mild            | 6.14                   | 0.939                  | 5.12                   | 0.368                  | 9.68                   | 0.105                  | 5.83                   | 1                      |
|                           | Severe          | 5.82                   |                        | 27.36                  |                        | 49.13                  |                        | 21.1                   |                        |

Note: The week wise disease duration is calculated after the onset of symptoms.
modulation of dendritic cells is associated with disease severity and could play a crucial role in COVID-19 pathogenesis. In-depth evaluation in terms of utility as a prognostic disease severity marker and treatment is warranted.

Involvement of monocytes, a key cell of the innate system, is documented in COVID-19. Monocytes from peripheral blood of healthy donors were shown to be positive for ACE2 receptor and could be infected by SARS-CoV-2. In contrast to previous reports, the proportion of monocytes were not different in MD and SD patients. Nonetheless, nonclassical monocytes (CD16+) did increase in both the patient categories. During the second week of the disease, SD patients exhibited significantly higher number of nonclassical monocytes than the MD group that could have led to further enhancement of proinflammatory cytokine secretion and worsening of the disease.

NK cells are one of the first cells to protect the host from viral infections. Lowering of these cells has been reported in COVID patients. In our patient series, NK cell frequencies were generally lower in SD patients reaching a significant difference during the second week. Increased frequency of activated NK cells (CD107a and IFN-γ expression) in SD patients is noteworthy and may be responsible for the aggravation of the infection by providing an inflammatory milieu.

4.2 T cell responses in SARS CoV-2 infection

T cell activation remains an essential event in effective cellular immune response against a variety of viral infections. In COVID-19, reduction, as well as unchanged frequencies of CD4 and CD8 T cells, have been reported. Our study did not find any alteration in CD4 and CD8 T cell frequencies in both patient categories resulting in unaltered CD4/CD8 ratios. However, a substantial increase in the activated CD8 T cells (HLA-DR and CD38+) in SD patients alone indicates the role of hyperactivation of CD8 T cells in disease severity. Of note, the difference was striking during the initial phase (first week) suggestive of a crucial role in disease pathogenesis. Prospective studies are needed to ascertain the utility of HLA-DR/CD38 positive CD8 T cells as a prognostic marker for disease severity. Following immunization with attenuated yellow fever and smallpox vaccines as models for acute viral infection, Miller et al. demonstrated that CD8 T cells with overexpression of HLA-DR and CD38/Ki67 markers reflect virus-specific CD8 T cells.

While confirming higher frequency of IL-2 + CD4 T cells in severe disease, our study revealed higher expression of IL-2 by CD4 T cells in SD patients during the first week of illness (Table 4) suggestive of an important
role in pathogenesis and possibility of being a prognostic marker of disease severity. Association of elevated IL-2 levels with disease severity is known for other coronaviruses such as SARS.\textsuperscript{24–26}

T cells of SD patients exhibited higher percentage of PD-1+ CD4 T cells that are characterized by poor effector function, sustained expression of inhibitory receptors, and reduced TCR sensitivity.\textsuperscript{27} IL-10, an inhibitory cytokine, not only prevents CD4 T cell proliferation but also can induce T cell exhaustion.\textsuperscript{28} Indeed, the SD patients showed higher plasma IL-10 levels which are speculated to be responsible for functional exhaustion of T cells.

Though we did not study virus-specific response, expression of CD40L on CD4+ T cells indicates sensitization of these cells in the SD patients that could be linked to the secretion of proinflammatory cytokines. Notably, hydroxychloroquine, one of the treatments for COVID, can attenuate progression to severe disease by repressing CD40L expression on activated T cells.\textsuperscript{29} Taken together, CD40L seems to be playing a critical role in COVID-19 pathogenesis. We observed higher CD40L expression by CD4 T cells in the SD patients. CD40L plays an important role in the germinal center formation.\textsuperscript{30} In this context, higher PRNT50 titers in the SD group are noteworthy. However, when MD and SD patients were compared with respect to disease duration, no significant difference emerged suggesting the involvement of additional factors.

### 4.3 Cellular factors responsible for humoral response

Though long-term follow up data is not yet available, a rapid decline of IgG-anti-SARS-CoV-2 antibodies along with the possibility of reinfection is suggested.\textsuperscript{31} On the other hand, severe disease has been associated with higher antibody titers (including neutralizing).\textsuperscript{7} Taken together, the dual role of antibodies in protection/pathogenesis of SARS-CoV-2 is not clear and needs immediate attention. As our own data identified the association of early and higher neutralizing antibodies with disease severity, we determined characteristics of key cellular players of humoral responses, that is, B cell and follicular T helper cell compartments in mild and severe disease.

While confirming a significant decline in B cell population in the SD patients\textsuperscript{2} and patients with longer viral RNA shedding,\textsuperscript{13} our data revealed that this difference was evident in the first week of disease. B cell sequestration in secondary lymph nodes leading to an early enhanced humoral immune response in severe cases seems a distinct possibility.

The germinal center formation is one of the major steps in the generation of virus-specific antibodies. Generally, T\textsubscript{FH} cells reside at lymph nodes or secondary lymphoid organs, but, in severe SARS CoV-2 infection, we observed an elevated frequency of T\textsubscript{FH} in peripheral blood suggestive of their hyperactivation. Moreover, IL-21 secretion was also higher in severe cases. IL-21 exerts an array of its actions through IL-21R expressed on B cells for the induction of affinity maturation and somatic hypermutation.\textsuperscript{32} Though the frequency of total memory B cell pool in SD cases was higher, these cells were equipped with lower IL-21 R expression. Thus, although IL-21 is expressed in abundant amount, due to the lack of receptor availability, hampering processes like affinity maturation and differentiation into antibody-secreting cells seems likely. Moreover, unused IL-21 may contribute to higher soluble plasma IL-21 levels and, being a member of the Th-17 family may aggravate lung injury in severe cases through cytokine storm mediated immune paralysis.

Multiple regression analysis signified an association of PD-1+CD4 T cells with neutralizing antibody titers that correlated with disease severity. Although PD-1 is an exhaustion marker expressed on activated CD4 and CD8 T cells, it reduces TCR ligand sensitivity imposing a more stringent selection threshold for competing B cells.\textsuperscript{33} It also promotes affinity maturation, improving the quality/neutralization capacity of antibodies in secondary lymph nodes. Thus, PD-1 expression by CD4 T cells seems to have a dual influence in COVID-19 pathogenesis.

Memory B cells formed during primary infection can induce long-lasting plasma cells to protect the host from recurrent infection. B cell maturation antigen (BCMA) expression is linked to the long lifespan of plasma cells.\textsuperscript{34} Activation of BCMA by BAFF (B cell–activating factor) increases expression of the antiapoptotic molecule myeloid cell leukemia-1 (Mcl-1), pointing to the mechanistic basis by which the BAFF/BCMA axis promotes long-term survival of plasma cells.\textsuperscript{35} We observed an early, higher frequency of memory B cells in the SD patients along with a lower proportion of BCMA + plasmablast cells. Memory B cells should be able to generate a protective immune response after reinfection while a low number of BCMA + plasma cells in SD patients may lead to rapid decline over time. Dynamics of antibodies over at least one year in relation to disease severity along with a simultaneous evaluation of relevant immunologic mechanisms will be able to address the most relevant public health issue of protection from SARS-CoV-2 exposure/re-exposure.
After recognition of IL-6 as the prognostic marker for severity in COVID-19, several groups including ours (this study) confirmed this observation. In fact, anti-IL-6 antibodies are being used in the treatment of SD patients. In accordance with acute inflammatory response, both IL-6 and IL-10 levels increased in SD patients while IL-4, an anti-inflammatory cytokine predominated in mild disease helping prevention of progression to severe disease. Relation of IL-4 levels with frequency of mDCs is noteworthy. Importantly, IL-4 is observed to reduce the expression of the ACE2 receptor and may partially contribute to restraining viral entry.

Our study has a few limitations. The sample size was limited and very few samples were available in the 4th week of disease. Due to lymphopenia and restricted sample volume, the study was limited to a few markers. Nonetheless, the results form the basis for planning in-depth analyses involving larger cohort and sequential

**FIGURE 7** Schematic presentation of the major findings: Multiparametric flow cytometry was used to enumerate immune cells from innate (NK cells, DCs, and monocytes and adaptive (T cells and B cells) immunity arms in COVID-19 patients presenting with mild or severe disease. The findings pointed out major defects in the maturation (CD80 and CD86 expression) of myeloid dendritic cells and reduction in plasmacytoid dendritic cell frequency, emphasizing compromised antigen presentation. Enhanced frequency of nonclassical monocytes could be an important event in maintaining vascular homeostasis in the inflammatory cytokine milieu formed due to the infection. Activated NK and CD8 T cell subsets observed in severe cases may enhance lung tissue injury and disease severity. Likewise, activation of TFH, and CD4 T cell compartments in these cases may lead to a transient higher humoral response observed during the acute phase of infection. However, whether these antibodies are protective or aid in disease severity remains unclear. Lower IL-21 receptor expression on B cells may lead to impaired proliferation and differentiation of B cells. Moreover, plasmablast cells showed a comparatively lower BCMA expression, a long term survival marker for plasma cells. Collectively, long term immunity is likely to be hampered, another observation being reported recently. The role of crucial immune cells identified in this study needs to be confirmed by functional assays.
follow up. Our results warrant exploring the role of IL-21/IL-21R expression ratio (memory B cells), CD40-CD40L interaction (CD4 T cells & B cells), and kinetics of BCMA expression on plasma cells in addressing crucial involvement of humoral response in SARS CoV-2 pathogenesis and protection.

In view of the involvement of multiple immune cell subsets and numerous markers, major findings of the study are outlined in Figure 7. In summary, while confirming previous findings, our study revealed that Indian patients exhibited a different set of immunological modulation in SARS CoV-2 infection and identified additional prospective severity prognostic markers such as dendritic cells, activated CD8 T cells, IL-2+ CD4 T cells, and follicular T helper cells. Confirmation in larger cohorts and in-depth functional assays to understand the underlying mechanism(s) remains the way forward.

ACKNOWLEDGMENTS
The authors would like to thank Mr. Tushar Bhosale for clinical sample management and Mr. Rahul Patil for statistical assistance. Thanks are due to Ms. Shweta, Mr. Aniket, and Ms. Prajakta for excellent technical help. Finally, we acknowledge the study participants for providing the necessary samples. This study was supported by DBT-BIRAC, India (Grant Number-BIRAC/BT/NBM0095/02/18).

CONFLICTS OF INTEREST
The authors declare no financial or commercial conflicts of interest.

AUTHOR CONTRIBUTIONS
VAA and AK conceived and designed the study. SS was responsible for PRNT work. ACM reviewed the results and contributed to the manuscript. SP and SL were responsible for subject recruitment, collection of relevant clinical information and samples as well as follow up. All authors contributed to the article and approved the submitted version.

ETHICAL STATEMENT
The entire study was approved by the Institutional Ethics Committee.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Archana Kulkarni-Munjé  http://orcid.org/0000-0002-2302-7594

REFERENCES
1. WHO. Dasbor WHO Coronavirus Disease. WHO. https://covid19.who.int
2. Wolff D, Nee S, Hickey NS, Marschollek M. Risk factors for Covid-19 severity and fatality: a structured literature review. Infection. Published online 2020.
3. Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature. 2020;583(7816):437-440.
4. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177-1179.
5. Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Med Mal Infect. 2020;50(4):382-383.
6. Liu Z, Li J, Chen D, et al. Dynamic Interleukin-6 Level Changes as a Prognostic Indicator in Patients With COVID-19. Front Pharmacol. 2020;11.
7. Liu L, To KKW, Chan KH, et al. High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerg Microbes Infect. Published online 2020:1-30.
8. Azzur AK, Akdis M, Azzur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy Eur J Allergy Clin Immunol. 2020;75(7):1564-1581.
9. Cox RJ, Brokstad KA. Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nat Rev Immunol. Published online 2020:20:581-582.
10. Chen Z, John, Wherry E. T cell responses in patients with COVID-19. Nat Rev Immunol. 2020;20(9):529-536.
11. Hao S, Lian J, Lu Y, et al. Decreased B cells on admission associated with prolonged viral RNA Shedding from the respiratory tract in coronavirus disease 2019: a case-control study. J Infect Dis. 2020;222(3):367-371.
12. Kulkarni R, Patil HP, Palkar S, Lalwani S, Mishra AC, Arankalle V. Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β-propiolactone-inactivated, whole virus-based indirect ELISA. J Virol Methods. Published online 2021;287:113996.
13. Pennica A, Conforti G, Falangone F, et al. Clinical management of adult coronavirus infection disease 2019 (COVID-19) positive in the setting of low and medium intensity of care: a short practical review. SN Compr Clin Med. 2020;2(6):694-699.
14. Cohen BJ, Audet S, Andrews N, Beeler J. Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine. 2007;26(1):59-66.
15. Zhang H, Wu T. CD4+ T, CD8+T counts and severe COVID-19: a meta-analysis. J Infect. 2020;81(3):e82-e84.
16. Wang S, Sun X, Zhou H, Zhu Z, Zhao W, Zhu C. Interleukin-4 affects the mature phenotype and function of rat bone marrow-derived dendritic cells. Mol Med Rep. 2015;12(1):233-237.
17. Pence BD. Severe COVID-19 and aging: are monocytes the key? GeroScience. 2020;42(4):1051-1061.
18. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020;202(5):756-759.
19. Market M, Angka I, Martel AB, et al. Flattening the COVID-19 curve with natural killer cell based immunotherapies. Front Immunol. 2020;11.
20. Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11.
21. Jiang M, Guo Y, Luo Q, et al. T-Cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of coronavirus disease 2019. J Infect Dis. 2020;222(2):198-202.
22. Miller JD, van der Most RG, Akondy RS, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008;28(5):710-722.
23. Schub D, Klemis V, Schneitler S, et al. High levels of SARS-CoV-2 specific T-cells with restricted functionality in patients with severe course of COVID-19. medRxiv. Published online 2020.
24. Huang KJ, Su IJ, Theron M, et al. An interferon-γ-related cytokine storm in SARS patients. J Med Virol. 2005;75(2):185-194.
25. Li CK, Wu H, Yan H, et al. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008;181(8):5490-5500.
26. Channappanavar R, Fett C, Zhao J, Meyerholz DK, Perlman S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J Virol. 2014;88(19):11034-11044.
27. Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion. Immunology. 2010;129(4):474-481.
28. Brooks DG, Walsh KB, Elsaesser H, Oldstone MBA. IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection. Proc Natl Acad Sci U S A. 2010;107(7):3018-3023.
29. Wu SF, Chang CB, Hsu JM, et al. Hydroxychloroquine inhibits CD154 expression in CD4+ T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling. Arthritis Res Ther. 2017;19(1):183.
30. Elgueta R, Benson MJ, De Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229(1):152-172.
31. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. Published online 2020;383:1085-1087.
32. Zotos D, Coquet JM, Zhang Y, et al. IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med. 2010;207(2):365-378.
33. Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201-1217.
34. O’Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199(1):91-97.
35. Lightman SM, Utley A, Lee KP. Survival of long-lived plasma cells (LLPC): Piecing together the puzzle. Front Immunol. 2019;10(MAY).
36. Liu T, Zhang J, Yang Y, et al. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med. Published online 2020.
37. de Lang A, Osterhaus ADME, Haagmans BL. Interferon-γ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology. 2006;353(2):474-481.

SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Kulkarni-Munjie A, Palkar S, Shrivastava S, Lalwani S, Mishra AC, Arankalle VA. Disease-duration based comparison of subsets of immune cells in SARS CoV-2 infected patients presenting with mild or severe symptoms identifies prognostic markers for severity. Immun Inflamm Dis. 2021;9:419-434. https://doi.org/10.1002/iid3.402